) The Southwest Oncology Group has evolved since its inception in 1956 into an adult multi-disease, multi-modality clinical research organization. This organization has grown to include 31 Full Member Institutions, 27 Community Clinical Oncology Program (CCOP) institutions, including 3 Minority-Based (MB) CCOPs, 4 Pilot Program CCOPs and 1 Pilot Program MBCCOP, 25 Urologic Cooperative Outreach Program (UCOP) institutions, and a network of approximately 1,434 Affiliate Program (AFFIL) investigators at 245 Affiliate institutions. In addition, 13 Group institutions also participate in the CTEP Minority Initiative program, which serves to enhance minority accrual in cancer clinical trials. More than 4,000 investigators, representing all research modalities, are members of the Group and actively participate in the registration of patients to cancer treatment and cancer control and prevention protocols. In addition, the Southwest Oncology Group coordinates two large intergroup chemoprevention trials funded by the Division of Cancer Prevention (DCP), the Prostate Cancer Prevention Trial (PCPT) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). More than 200 PCPT institutional sites affiliated with the Southwest Oncology Group and two other cooperative groups participate in this trial. Currently, over 200 institutional sites affiliated with the Southwest Oncology Group, 4 other cooperative groups, the Veterans Affair Cooperative Studies Group and the Canadian Urologic Oncology Group have been chosen to participate in the SELECT trial. The Southwest Oncology Group is also committed to representative accrual of women and minority patients and subjects to Group clinical trials. To this end, the Group has developed an extremely active Committee on Women and Special Populations, which serves to evaluate and enhance the accrual of women, minorities and special populations (e.g., elderly) to Group trials, identify and address special concerns regarding women?s health issues in the cooperative group setting, and act as a direct liaison with women?s and minority health groups, such as the Office of Research on Women?s Health (ORWH) and the Office of Research on Minority Health (ORMH). The Southwest Oncology Group has continued to pursue the goals of the National Cancer Institute CCOP and MB-CCOP program through innovative membership and cancer prevention and control programs, extensive training and educational opportunities for the Group membership, and unsurpassed excellence in patient accrual and quality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037429-18S1
Application #
6642236
Study Section
Special Emphasis Panel (ZCA1 (J1))
Program Officer
Parnes, Howard L
Project Start
1983-09-30
Project End
2006-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
18
Fiscal Year
2002
Total Cost
$884,086
Indirect Cost
Name
Cancer Therapy and Research Center
Department
Type
DUNS #
010550366
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Cook, Michael B; Barnett, Matthew J; Bock, Cathryn H et al. (2018) Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. Gut :
Hershman, Dawn L; Unger, Joseph M; Greenlee, Heather et al. (2018) Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 320:167-176
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Lance, Peter; Alberts, David S; Thompson, Patricia A et al. (2017) Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila) 10:45-54
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:
Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W et al. (2017) Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2:27
Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557

Showing the most recent 10 out of 368 publications